Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer

Inclusion Criteria: 1. Be capable of understanding the informed consent form (ICF) and complying with the protocol, and must sign the ICF prior to the performance of any study related procedures; 2. Have cancer that is nonresponsive despite prior treatment with current standard of care regimens or for whom there are no available effective therapies; 3. Have measurable or evaluable neoplastic disease; 4. Be greater than or equal to age 18; 5. Have and ECOG Performance Status score of less than or equal to 2; 6. Have adequate organ function defined by: 1. Liver function tests (AST \& ALT) less than or equal to 3 times the upper limit of normal (ULN); 2. Bilirubin less than or equal to 1.5 X ULN; 3. Serum Creatinine less than or equal to 1.5 X ULN; 4. Hemoglobin greater than or equal to 8.0 g/dL; 7. Have recovered or stabilized from clinically significant toxicities of prior chemotherapy, surgery, or radiotherapy; 8. Have left ventricular ejection fraction (LVEF) of greater than or equal to 45% by multiple gated acquisition (MUGA) scan or echocardiogram. Exclusion Criteria: 1. Have had a prior serious, uncontrollable hypersensitivity reaction to Cremophor EL; 2. Be pregnant or lactating (women of childbearing potential must use appropriate birth control (abstinence, barrier methods, oral contraceptives and/or intrauterine devices) during the entire duration of the study, or the patient must be surgically sterile (with documentation in the patient's medical records); 3. Receive any other anticancer treatment or investigational therapy within 14 days prior to day 1; or within 6 weeks after prior mitomycin C or nitrosourea. Patients with advanced prostate cancer may continue to receive leutinizing hormone-releasing hormone (LHRH) therapy while in this study; 4. Have previously enrolled in this trial. -